PTEN Expression, Not Mutation Status in TSC1, TSC2, or mTOR, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.
Martin H VossYing-Bei ChenAlbert ReisingMahtab MarkerJiayuan ShiJianning XuIrina OstrovnayaVenkatraman E SeshanAlmedina RedzematovicParul PatelXia HanJames J HsiehA Ari HakimiRobert J MotzerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Association between mutation status for TSC1/TSC2/mTOR and therapeutic outcome on everolimus was not confirmed. Clinically meaningful differences in PFS were seen based on PTEN expression by IHC, lost in >50% of patients.